Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,429 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: opiates Clear all

Conditions: Moderate-severe Pain
Interventions: ALO-02; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 16
States / cities: Lancaster, California • Los Angeles, California • Sacramento, California + 4 more

Conditions: Erectile Dysfunction
Interventions: Naltrexone HCL/ Yohimbine HCL; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Postdural Puncture Headache, Post-Lumbar Puncture Headache, Cerebrospinal Fluid Leaks
Interventions: Morphine, Saline; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pain Management
Interventions: Tramadol, Morphine, Placebo; Drug · Other
Lead sponsor: Avenue Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Pasadena, California • Houston, Texas • San Antonio, Texas

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 21 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1992
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Opioid Use Disorder
Interventions: BIOPIN-6 Active Implant with Naltrexone, BIOPIN-6 Placebo Implant; Combination Product · Device
Lead sponsor: Akyso Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Osteoarthritis
Interventions: Oxycodone, Placebo, PF-000592379; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 21
States / cities: Mobile, Alabama • Tucson, Arizona • Carmichael, California + 17 more

Conditions: Healthy
Interventions: Buprenorphine transdermal patch; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Osteoarthritis, Chronic Pain
Interventions: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release), Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years and older
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 81
States / cities: Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 69 more

Conditions: Postoperative Pain
Interventions: Buprenorphine, Sterile saline, lidocaine, epinephrine (Local anesthetic); Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pain
Interventions: Hydromorphone; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: The Bronx, New York

Conditions: Opioid-use Disorder
Interventions: Interview, Surveys; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Opioid Use Disorder
Interventions: ASP8062, Placebo ASP8062, buprenorphine/naloxone; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Opioid Use Disorder
Interventions: Buprenorphine; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Heroin Dependence
Interventions: Buspirone; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 25 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Substance Use Disorders
Interventions: ThermoNeuroModulation TNM Device; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Total Knee Arthroplasty
Interventions: Oxycodone, Placebo Oral Tablet; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 89 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Pain
Interventions: Methadone, methadone and morphine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid Use, Opioid Dependence, Opioid-use Disorder, Narcotic Use, Back Pain, Back Injuries, Chronic Pain, Chronic Low-back Pain, Pain, Chronic, Pain;Back Low;Chronic, Pain, Back
Interventions: Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet, Naproxen 500 Mg, Opioids; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Smoking Cessation
Interventions: Naltrexone (Vivitrol), Bupropion; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Pain, Pain, Opioid Withdrawal (Disorder), Opioid Use Disorder
Interventions: Cebranopadol, Placebo; Drug
Lead sponsor: Adneuris Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: North Canton, Ohio • Houston, Texas

Conditions: Nicotine Dependence
Interventions: Naltrexone, Transdermal nicotine replacement, Behavioral counseling; Drug · Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Opioid-use Disorder
Interventions: Buprenorphine; Drug
Lead sponsor: MaineHealth; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Portland, Maine

Search by objective public record fields.

Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain

Effects of Yohimbine and Naltrexone on Sexual Function

Incidence of Headache Following an Unintentional Dural Puncture

Tramadol Versus Placebo and Morphine in the Management of Post-Operative Pain Abdominoplasty

Buprenorphine Dosing Interval - 5

Study of the BIOPIN 6 Naltrexone Implant in Healthy Adults

A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee

Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods

A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee

Efficacy of Buprenorphine on Postoperative Endodontic Analgesia

Association Between Body Size and Response to Hydromorphone in ED

Obstetric Pain Management for Women With Opioid Use Disorder (QUEST)

A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder

Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use

Effects of Buspirone in Opiate Withdrawal

Investigating the Efficacy of Caloric Vestibular Stimulation in the Treatment of Substance Use Disorders

Buprenorphine Detox With Two Types of Treatment. BBD II - 11

Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty

Comparison of A Single Dose Combination of Methadone and Morphine With Morphine Alone for Treating Post-operative Pain

Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure

Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia

A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain

Targeted Interventions for Weight-Concerned Smokers

The Effect of Buprenorphine Continuation for Patients With Opioid Use Disorder